Table 1.
Considerations when designing a target trial using electronic health records.
Table 2.
Specification of target trial protocol and emulation in northwestern medicine’s enterprise data warehouse (NMEDW).
Table 3.
Demographic and clinical characteristics of included patients with rheumatoid arthritis at baseline and stratified by treatment strategy after 24 months, northwestern medicine, January 2000–June 2020.
Fig 1.
MACE-free survival curves comparing methotrexate monotherapy versus addition of second-line DMARD therapy, northwestern medicine, January 2000–June 2020. Caption: Black lines represent survival curves. Dashed gray lines represent 2.5 and 97.5 bootstrapped percentiles from 500 re-samples. Sensitivity analyses included: (B) linear time, (C) linear and quadratic time, (D) used 12-month grace period, (E) require diagnosis of RA≥6 months before time zero, (F) exclude individuals who used hydroxychloroquine as additional therapy.
Table 4.
Hazard ratios, risk differences, and restricted mean survival times for 5-year risk of MACE comparing methotrexate monotherapy and addition of second-line DMARD therapy, northwestern medicine, January 2000–June 2020.